Effect of photopheresis on lymphocyte population in children with newly diagnosed type 1 diabetes.
In recent years photopheresis has been claimed to be an effective form of immunomodulation. It has also been shown to have an effect on the disease process at the onset of type 1 diabetes. In a double-blind, placebo-controlled randomized study, we analyzed if the effect of photopheresis in children with newly diagnosed diabetes is related to changes in the balance of lymhocyte populations. We also analyzed if lymphocyte subsets were related to recent infection, mild or aggressive disease manifestations, heredity, or gender. Nineteen children received active treatment with photopheresis, while 21 children received sham pheresis (placebo group). No influence of a history of previous infection, heredity, or certain clinical parameters on lymphocyte subsets was found. At the onset of type 1 diabetes, girls showed a higher proportion and a larger number of T cells (CD3+) and T-helper cells (CD4+) and a higher proportion of naïve CD4+ CD45RA+ cells. In the placebo group, an increase in the number of subsets with the activated phenotype in both the CD4(CD29+) and the CD8 (CD11a+) compartments was noted during the course of the study. These changes did not occur in the photopheresis group. No relation between lymphocyte subsets and clinical outcome was found 1 year after the treatment with photopheresis. In conclusion, we found no major effect of photopheresis on lymphocyte populations in a group of children with newly diagnosed type 1 diabetes. However, in the placebo group the proportions of activated CD4 and CD8 cells increased over time. Since these changes did not occur in the actively treated group, our findings suggest that photopheresis may have some suppressive effects.
Ernerudh
J
J
Division of Clinical Immunology, Department of Molecular and Clinical Medicine, Faculty of Health Sciences, Linköping University, Linköping, Sweden.
Ludvigsson
J
J
Berlin
G
G
Samuelsson
U
U
D000293:Adolescent; D002648:Child; D003922:Diabetes Mellitus, Type 1 / Q000628:therapy*; D005192:Family Health; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy; D007239:Infections; D008213:Lymphocyte Activation; D016131:Lymphocyte Subsets / Q000528:radiation effects; D008214:Lymphocytes / Q000528:radiation effects*; D008297:Male; D010641:Phenotype; D017893:Photopheresis; D011379:Prognosis; D012737:Sex Factors